Bio-Techne (TECH) – Analysts’ Weekly Ratings Changes

Bio-Techne (NASDAQ: TECH) recently received a number of ratings updates from brokerages and research firms:

• 7/9/2026 – Bio-Techne was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $73.00 price target on the stock, up from $62.00.
• 7/6/2026 – Bio-Techne was downgraded by Evercore Inc from “strong-buy” to “hold”.
• 6/30/2026 – Bio-Techne was downgraded by Benchmark Co. from “buy” to “hold”.
• 6/29/2026 – Bio-Techne was downgraded by TD Cowen from “buy” to “hold”. They now have a $73.00 price target on the stock, up from $65.00.
• 6/26/2026 – Bio-Techne was downgraded by Citigroup Inc. from “buy” to “neutral”. They now have a $73.00 price target on the stock, up from $70.00.
• 6/26/2026 – Bio-Techne was given a new $73.00 price target by Stephens. They now have an “equal weight” rating on the stock.
• 6/26/2026 – Bio-Techne was downgraded by Deutsche Bank Aktiengesellschaft from “buy” to “hold”. They now have a $73.00 price target on the stock.
• 6/26/2026 – Bio-Techne was downgraded by Stephens from “strong-buy” to “hold”.
• 6/26/2026 – Bio-Techne had its price target raised by Robert W. Baird from $49.00 to $73.00. They now have a “neutral” rating on the stock.
• 6/25/2026 – Bio-Techne was downgraded by William Blair from “outperform” to “market perform”.
• 6/25/2026 – Bio-Techne was given a new $73.00 price target by Leerink Partners.
• 6/25/2026 – Bio-Techne was downgraded by Leerink Partners from “strong-buy” to “hold”.
• 6/25/2026 – Bio-Techne was upgraded by Evercore Inc from “hold” to “strong-buy”.
• 6/23/2026 – Bio-Techne had its “buy” rating reaffirmed by TD Cowen.
• 6/11/2026 – Bio-Techne is now covered by Piper Sandler. They set a “neutral” rating and a $65.00 price target on the stock.
• 6/11/2026 – Bio-Techne is now covered by Piper Sandler. They set a “neutral” rating and a $65.00 price target on the stock.
• 6/8/2026 – Bio-Techne was downgraded by Zacks Research from “hold” to “strong sell”.
• 5/14/2026 – Bio-Techne was given a new $62.00 price target by Royal Bank Of Canada. They now have an “outperform” rating on the stock.
• 5/14/2026 – Bio-Techne was upgraded by Royal Bank Of Canada to “moderate buy”.

Bio-Techne Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Stockholders of record on Monday, May 18th were issued a dividend of $0.08 per share. The ex-dividend date of this dividend was Monday, May 18th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.4%. Bio-Techne’s dividend payout ratio is currently 46.38%.

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.